We have located links that may give you full text access.
Clinical and histological predictors of contralateral breast cancer.
European Journal of Surgical Oncology 1999 December
AIMS: Women previously treated for primary operable breast cancer are at increased risk of developing cancer in the contralateral breast. The purpose of this study was to assess the annual incidence of metachronous contralateral breast cancer (CBC) and to identify factors that predict for its development.
METHODS: A retrospective study was performed on 3211 women aged </=70 years treated for primary operable breast cancer between 1975 and 1995.
RESULTS: Eighty-three developed CBC prior to locoregional or distant recurrence from the first primary. The clinical incidence of CBC was 6.4 per 1000 women years, three to four times the risk of occurrence of breast cancer in the general female population (or a risk of six to eight times to the remaining breast). Strong family history, age of onset <50 years and lobular histology were significant factors predicting for CBC in univariate and multivariate models. Other clinical factors (previous hormone therapy, chemotherapy, radiotherapy) or histological factors (DCIS, invasive tumour size, grade, vascular invasion, lymph node and oestrogen receptor status) were not significant predictors for CBC.
CONCLUSIONS: In women previously treated for primary operable breast cancer, early age of onset and a strong family history are predictors for the subsequent development of metachronous CBC. Ipsilateral mastectomy with contralateral prophylactic mastectomy with or without immediate breast reconstruction is a reasonable option for a young woman diagnosed with breast cancer and who has a strong family history, particularly if the cancer has histological features suggesting a good prognosis.
METHODS: A retrospective study was performed on 3211 women aged </=70 years treated for primary operable breast cancer between 1975 and 1995.
RESULTS: Eighty-three developed CBC prior to locoregional or distant recurrence from the first primary. The clinical incidence of CBC was 6.4 per 1000 women years, three to four times the risk of occurrence of breast cancer in the general female population (or a risk of six to eight times to the remaining breast). Strong family history, age of onset <50 years and lobular histology were significant factors predicting for CBC in univariate and multivariate models. Other clinical factors (previous hormone therapy, chemotherapy, radiotherapy) or histological factors (DCIS, invasive tumour size, grade, vascular invasion, lymph node and oestrogen receptor status) were not significant predictors for CBC.
CONCLUSIONS: In women previously treated for primary operable breast cancer, early age of onset and a strong family history are predictors for the subsequent development of metachronous CBC. Ipsilateral mastectomy with contralateral prophylactic mastectomy with or without immediate breast reconstruction is a reasonable option for a young woman diagnosed with breast cancer and who has a strong family history, particularly if the cancer has histological features suggesting a good prognosis.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app